Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA) identifier:
NCT04644068 (

Advanced ovarian, breast, prostate or pancreatic cancer

Study Contact Information:

For more information, contact the study coordinator:
Natalie Velez by email at [email protected]

About the Study

PETRA is a study of a new, investigational PARP inhibitor, AZD5305 taken orally, either alone or combined with other anti-cancer therapies in patients with advanced ovarian, breast, prostate or pancreatic cancer with an inherited mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D. The combination available and which group you are assigned to will depend on your cancer type and mutation and when you join the study.

What the Study Entails

Study Sites

New York
New York City, NY
Memorial Sloane Kettering
Allison Schram

Houston, TX 
MD Anderson
Dr Timothy Yap
Contact: Natalie Velez by email at [email protected]

This Study is Open To:

Participants 18 years and older with the following may be eligible to participate:


This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.